Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24879798.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0820 and PMC identifier 4330468.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immunosuppressive checkpoints mediated by IDO, CTLA4, and PD1/PDL1 play a critical role in glioma progression and the efficacy of immunotherapies. Combined blockade of these immunosuppressive checkpoints in a glioma model elicited long-term survival. This combined blockade adds to the armamentarium of anti-glioma therapies, which could be implemented in clinical trials. Clin Cancer Res; 20(20); 5147-9. ©2014 AACR.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- B7-H1 Antigen
- Brain Neoplasms
- CTLA-4 Antigen
- Indoleamine-Pyrrole 2,3,-Dioxygenase